IGF, Université de Montpellier, CNRS, INSERM, Montpellier, France.
Montpellier Ressources Imagerie, Biocampus, Université de Montpellier, CNRS, INSERM, Montpellier, France.
Stem Cell Reports. 2022 Apr 12;17(4):835-848. doi: 10.1016/j.stemcr.2022.02.005. Epub 2022 Mar 10.
Tumor recurrence is often attributed to cancer stem cells (CSCs). We previously demonstrated that down-regulation of Pregnane X Receptor (PXR) decreases the chemoresistance of CSCs and prevents colorectal cancer recurrence. Currently, no PXR inhibitor is usable in clinic. Here, we identify miR-148a as a targetable element upstream of PXR signaling in CSCs, which when over-expressed decreases PXR expression and impairs tumor relapse after chemotherapy in mouse tumor xenografts. We then develop a fluorescent reporter screen for miR-148a activators and identify the anti-helminthic drug niclosamide as an inducer of miR-148a expression. Consequently, niclosamide decreased PXR expression and CSC numbers in colorectal cancer patient-derived cell lines and synergized with chemotherapeutic agents to prevent CSC chemoresistance and tumor recurrence in vivo. Our study suggests that endogenous miRNA inducers is a viable strategy to down-regulate PXR and illuminates niclosamide as a neoadjuvant repurposing strategy to prevent tumor relapse in colon cancer.
肿瘤复发通常归因于癌症干细胞(CSCs)。我们之前证明,下调妊娠相关 X 受体(PXR)可降低 CSCs 的化疗耐药性并防止结直肠癌复发。目前,临床上尚无可用的 PXR 抑制剂。在这里,我们确定 miR-148a 是 CSCs 中 PXR 信号的上游可靶向元件,当过度表达时,它会降低 PXR 的表达,并在小鼠肿瘤异种移植后化疗后损害肿瘤复发。然后,我们开发了荧光报告基因筛选来鉴定 miR-148a 的激活剂,并确定驱虫药尼氯硝唑作为 miR-148a 表达的诱导剂。因此,尼氯硝唑降低了结直肠癌细胞系中 PXR 的表达和 CSC 的数量,并与化疗药物协同作用,以防止体内 CSC 的化疗耐药性和肿瘤复发。我们的研究表明,内源性 miRNA 诱导物是下调 PXR 的可行策略,并阐明了尼氯硝唑作为预防结肠癌肿瘤复发的新辅助重新定位策略的潜力。